Navigation Links
Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results
Date:11/13/2008

MONTVALE, N.J., Nov. 13 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY), today reported its financial results for the third quarter ended September 30, 2008.

"Our results reflect continued clinical progress on our programs and our commitment to translate that progress into innovative therapies," stated Vaughn M. Kailian, President and Chief Executive Officer of Memory Pharmaceuticals. "We expanded our agreement with Roche to enhance our ongoing Phase 2 trial for R3487/MEM 3454 in cognitive impairment associated with schizophrenia, or CIAS, resulting in accelerated milestone payments to Memory. We have been pleased with the pace of enrollment in the Phase 2 CIAS trial, and we expect to achieve our enrollment goal for the trial shortly, which will trigger a $5.0 million payment from Roche. During the quarter, we also achieved a milestone related to the Phase 2 CIAS trial under our equity financing agreement with SMRI, triggering an additional investment by the firm. In addition, we completed the final study in our Phase 1 program for R4996/MEM 63908 and are on track to report top-line results from the entire program before year-end."

Financial Results

For the quarter ended September 30, 2008, the Company reported a net loss of $8.9 million, or $0.11 per share, compared to a net loss of $6.2 million, or $0.09 per share, for the same period in 2007. For the nine months ended September 30, 2008, the Company reported a net loss of $34.8 million, or $0.46 per share, compared to a net loss of $25.7 million, or $0.36 per share, for the same period in 2007.

For the quarter ended September 30, 2008, the Company reported revenue of $4.3 million, compared to revenue of $5.0 million for the same period
'/>"/>

SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Miniaturizing memory: Taking data storage to the molecular level
2. Memory Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference
3. Memory Pharmaceuticals Granted Extension to Comply with NASDAQ Listing Requirements
4. Memory Pharmaceuticals Provides Update on NASDAQ Listing Status
5. Memoirs of a qubit: Hybrid memory solves key problem for quantum computing
6. Blanchette Rockefeller Neurosciences Institute Hosts First-Ever International Forum on Memory and Memory Disorders and Dedicates New $30 Million Research Facility
7. Jellyfish Protein Shows Potential to Help With Memory
8. Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908
9. SAFC Hitech(TM) Successfully Demonstrates Device-Quality GST Precursors For Phase Change Memory Applications
10. Memory Pharmaceuticals Closes Final Tranche of Equity Financing with The Stanley Medical Research Institute
11. Memory Pharmaceuticals to Announce Second Quarter 2008 Results on Wednesday, August 13, 2008

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...r to also Visit Detroit , ...a, French Ambassador for International Investment,...cy, , , , ,What: Ambassador Appia is available to...itiatives adopted by France to further develop the...vation and development., , ,When: Available for In...
(Date:11/24/2009)...ntario, Nov. 24 Dow Agro...e assets of Hyland Seeds, a division of Thompsons ...nd Seeds will further expand Dow AgroSciences, cur... introduction of SmartStax(TM) in 2010 and D...y in corn in 2012. The transactional close is expe...
(Date:11/24/2009)...are employment grew by 29,000 jobs in October, an...t growth during the U.S. recession. However, clini...health systems are coming closer to having to actu...strators. , (Vocus) Novem...rowing in October despite the shedding of jobs in ...
(Date:11/24/2009)...Nov. 24 NeurogesX, Inc. ...sed on developing and commercializing novel pain m...DiTonno, President and Chief Executive Officer, is...fray Health Care Conference, to be held December 1... New York. ,, Mr. DiTonno and Stephen Ghiglier...
Breaking Biology Technology:Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3
...or, INDIANAPOLIS, Sept. 22 AIT Laboratories, a l...harmaceutical testing facility,is announcing the e...osen,an industry veteran to lead the division. AIT...f scientific officer of West Lafayette-based,Bioan...ecutive director of,Pharma Services. "Ron brings 3...
.... Finn, Jr.,C.P.A. ("Finn"), Assignee of the asset...f creditors, announced today that all oral drug de...led bid auction on October 10,2008., The three p...d Oral Delivery System 2. Biological Factors Affe..., 3. Pharmacokinetics Evaluation of Topiramate Im...
... the American Society for, Therapeutic Radiology ... 21-24, 2008, BOSTON,...tems (NYSE: VAR ), world leader in advanced radio...sorders, is showcasing a full,spectrum of technolo...,precise cancer treatments at the 50th annual meet...
Other Biology Technology:AIT Laboratories Expands Pharma Services 2AIT Laboratories Expands Pharma Services 3Spherics, Inc. Presented Three Key Technologies (BIOROD(TM), BIOGIT(TM), and SPHEROMER(TM)) at the 35th Annual Meeting of Controlled Release Society 2Varian Medical Systems Exhibits a New Version of RapidArc(TM) Radiotherapy Technology and Other Products for Fast, Precise Cancer Treatment 2Varian Medical Systems Exhibits a New Version of RapidArc(TM) Radiotherapy Technology and Other Products for Fast, Precise Cancer Treatment 3Varian Medical Systems Exhibits a New Version of RapidArc(TM) Radiotherapy Technology and Other Products for Fast, Precise Cancer Treatment 4
(Date:11/24/2009)...of debate. A high-profile study a few years ago su...arbon from trees and leaves, evidence for a very c...ystems. , But new research from the University o...Algae provide a much richer diet for fish and othe...is week in the Proceedings of the National Academ...
(Date:11/23/2009)... Applied mathematicians dissected the morphology o...teristic long leaf with a saddle-like arc midsecti... simple cause of the lily,s fan-like shapeelastic ...ial growthwas revealed by using an equally simple ...g, a postdoctoral student at Harvard,s School of E...
(Date:11/23/2009)..."incontrovertible evidence" that the volcanic supe...73,000 years ago deforested much of central India,...report. , The volcano ejected an estimated 800 c...g a crater (now the world,s largest volcanic lake)...e. Ash from the event has been found in India, the...
Breaking Biology News(10 mins):Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3The cause behind the characteristic shape of a long leaf revealed 2Supervolcano eruption -- in Sumatra -- deforested India 73,000 years ago 2SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE 2009 BIOCOM INVESTOR CONFERENCE 14539 1SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE 2009 BIOCOM INVESTOR CONFERENCE 14539 2Abaxis to Report Second Quarter Fiscal 2010 Financial Results Tuesday October 27 2009 5597 1Abaxis to Report Second Quarter Fiscal 2010 Financial Results Tuesday October 27 2009 5597 2AFFiRiS AG Encouraging Results From Phase I Studies of two Alzheimers Candidate Vaccines Trigger a EUR 10 Million Milestone Payment 5594 1AFFiRiS AG Encouraging Results From Phase I Studies of two Alzheimers Candidate Vaccines Trigger a EUR 10 Million Milestone Payment 5594 2AFFiRiS AG Encouraging Results From Phase I Studies of two Alzheimers Candidate Vaccines Trigger a EUR 10 Million Milestone Payment 5594 3
...e most extensive field campaign ever to investigat...The mission is poised to help scientists identify ...n the Arctic. , The recent decline of sea ice is ...t environmental changes related to climate warming...mosphere,s role in this climate-sensitive region w...
...ch finds fresh evidence that urbanization in the U...cies of migratory birds. , But the six-year study...anations of why urban areas are so hostile to some...hat common nest predators in urban areas such as ...illing young birds in greater numbers than in rura...
...ondering: Will April be the cruelest month? , ...y reminiscent of 1993 and 1994, back-to-back years... causing nearly $20 billion of economic damage, da...illing at least 38 people. , Parallels th...ation in late winter and early spring and early fl...
Other Biology News:NASA launches airborne study of arctic atmosphere, air pollution 2NASA launches airborne study of arctic atmosphere, air pollution 3Some migratory birds can't find success in urban areas, study finds 2Some migratory birds can't find success in urban areas, study finds 3Geologist decries floodplain development 2Geologist decries floodplain development 3
Mouse Anti-Catenin, beta, N-terminal (exon 2) Monoclonal Antibody, Unconjugated, Clone BDI710 from Meridian Life Science, Inc.
Anti-CaMKII (Calmodulin-dependent Protein Kinase II) Monoclonal Antibody, Unconjugated, Clone 6G9 (2) from CHEMICON
Rabbit Anti-SLAP-2 Polyclonal Antibody, Unconjugated from Calbiochem
...eous ligand immobilization can be coupled with a l...eptor to create an affinity matrix of choice. Affi...a primary amines. Affi-Gel 10 gel couples neutral ... 15 gel couples acidic proteins with pI less than ...
Biology Products: